Life Sciences Archive » September, 2023

Life Sciences - September, 2023

335 articles

• US Chamber Loses Bid To Stop Medicare Drug Price Talks
• Gilead Must Face HIV Drug Design-Defect Claims At Trial
• 'Prescription Diet' Pet Food Buyers Win Cert. In Fraud Suit
• FDA Wants Oversight Of Lab-Developed Tests
• Ex-USPTO Head Says Breaking Patents Won't Cut Drug Prices
• Generic Cos. Must Face IP Claims Over Novartis Blockbuster
• Pro Say: A Cheat Sheet For The New Supreme Court Term
• States Ask To Block Sandoz Spinoff Over Price-Fixing Claims
• HHS Watchdog Says Pathology Deal Carries Kickback Risk
• Atty Files FOIA Suit Over HHS Pot Recommendation Letter
• Hospice Head Gets 4 Years For $150M Medicare Billing Fraud
• Avoiding The Ethical Pitfalls Of Crowdfunded Legal Fees
• O'Melveny Steers Cancer-Focused Biotech Firm's $58M IPO
• 'False' Info Led To Pfizer Insider Trading Case, Court Told
• Texas Firm Tells Appeals Court Anti-SLAPP Move Is Stall Effort
• 'Administrative State' Attacks Soar To High Court Crescendo
• Kirkland-Led Cinven Paying $1.3B In Synlab Buyout
• UK Litigation Roundup: Here's What You Missed In London
• 4 Pharma Industry Arguments Against CMS Drug Pricing Plan
• Mich. Judge Trims Contract Breach Suit Against R&B Singer
• First-Time Advocates Dominate High Court's Fall Schedule
• Taxation With Representation: Skadden, Ropes & Gray
• 5 Supreme Court Cases To Watch This Fall
• Fed. Circ. Forecast: Intel Looks To Sink $2B Patent Loss
• Opioid Special Master's Email Doesn't Betray Bias, Court Told
• SEC's 'Shadow Trading' Test Case Fails Miserably, Court Told
• Boehringer Bemoans Medicare Drug Price Talks As 'A Sham'
• Regeneron Wins Higher Bar At Trial For FCA Kickback Theory
• Texas Appeals Court Upholds Temporary Block Of Delta-8 Ban
• Watchdog Questions Competition In $45M KPMG COVID Deal
• Fed. Circ. Won't Revive Masimo Medical Alarm IP
• Imerys Insurers Will Get Mediator For Ch. 11 Settlement Effort
• MSN Beats Allergan's Generic Patent Row In Bench Trial
• As AI Pricing Tools Evolve, So Does Antitrust Risk
• Monsanto Wins Directed Verdict In Missouri Roundup Trial
• Bradley Arant Accused Of 'Double-Talk' Over Deposition Texts
• Eastman Chemical To Sell Texas City Operations For $490M
• Issues Ahead As Psychedelic Medicine Faces Pivotal Moment
• Ohio Justices Query State's Bid To Lift Block On Abortion Ban
• Monsanto Questions Relevance Of PCB Rat Research At Trial
• Roundup Plaintiff Rests Case In Mo.
• Sutter Health Nears Win In Physician's Suit Alleging Kickbacks
• SEC Doles Out $1.5M In Fines Over Insider Reporting Failures
• Noteholders, Shareholders Call Mallinckrodt Ch. 11 Plan Unfair
• Implant Co. Loses Appeal On FCA Misbranding Question
• Mylan Dodges Contract Breach Claim In Takeda IP Fight
• Takeda Unit, Ex-Worker Resolve Bias And Retaliation Suit
• AstraZeneca Seeks Quick Win In Drug Price Negotiation Fight
• 7th Circ. Judge Unsure X-Ray Tech Was Fired For Complaint
• Avalyn Pharma Raises $175M In Series C Financing Round
• EPA IG Wants Better Oversight Of Great Lakes Grant Program
• Biotech Biz Evozyne Closes $81M Series B Funding Round
• Surgalign Gets Texas Judge's OK For Ch. 11 Plan
• Virgin Pulse To Merge With HealthComp In $3B Deal
• 3rd Circ. Won't Revive Malpractice Suit Against Polsinelli
• Bracing For Regulatory Delays As Shutdown Looms
• Mintz Bolsters IP And Finance Benches With 2 New Partners
• An Overview Of 6 PBM Bills Moving Through Congress
• McKinsey Strikes $230M Opioid Deal With Gov'ts And Schools
• Monsanto PCBs Didn't Show Up In Testing, Seattle Jury Told
• Eli Lilly Gets $177M Teva Migraine Drug Patent Verdict Tossed
• Eyelid Wiper New Enough To Judge To Keep Patent Suit Alive
• Food 'Fraud' Can't Apply To Nursing Homes, NJ Justices Told
• Axsome Beats Securities Suit Over Migraine Drug, For Now
• Hospital Freed From Mo. Man's Suit Over Wife's Sperm Swap
• Anti-Fraud Group Defends FCA's Whistleblower Provisions
• Amazon, Google Give Views On Counterfeit Goods
• Judge Limits Flint Expert's Testimony On 'Community Trauma'
• Doctors Back 5th Circ. Bid To Nix 'No Surprises' Billing Reg
• Enviro Groups Urge EPA To Regulate Rail Cars' Coal Pollution
• Sutter Health Bills Included Unnecessary Charges, Judge Told
• 3 Firms Build Alfasigma's Nearly $800M Intercept Pharma Buy
• Astellas Sued In Del. Over Millions In Drug Milestone Payouts
• Judge OKs Fees For Talc Lawyers In J&J Unit's First Ch. 11
• Vanda Challenges FDA's Clearance Of Generic Sleep Drug
• Exclusivity Loss Holds Power In Trade Secret Damages Claims
• Florida Man Admits To $16.7M HIV Drug Fraud Conspiracy
• The 2023 Law360 Pulse Social Impact Leaders
• Why Law Firm ESG Is Likely Here To Stay
• What Large Language Models Mean For Document Review
• Proskauer, VC Settle Over Alleged $636M Copy-Paste Error
• Corning Prevails In Long-Running Fight Over Cell-Culture IP
• Monsanto's 1971 PCB Study Had Fake Data, Seattle Jury Told
• PBM Group Must Respond To 10th Circ. En Banc Petition
• IBM, J&J Face Class Action Over August Patient Data Breach
• Sutter Health Judge Doubts Plaintiff's Expert In $519M Trial
• NC Abortion Law 'Irrational,' Federal Court Hears
• Target Must Face Bulk Of Suit Over 'Non-Drowsy' Flu Medicine
• Checking In On How SuperValu Has Altered FCA Litigation
• Catching Up With Delaware's Chancery Court
• PharMerica Unit Hit With Data Breach Class Action In Calif.
• Reed Smith VC Chair Joins Dentons' Tech Practice In Calif.
• Class Seeks $1.1M Atty Fees In CVS Lidocaine Label Suit
• Future Paths For AI Inventorship After Justices' Thaler Denial
• Participating In Living History Makes Me A Better Lawyer
• How Attys Can Weather The Next Disaster Litigation Crisis
• Roundup User Tells Jury Agriculture Jobs Didn't Cause Cancer
• Philly PD's Win In Miscarriage Suit Tossed Over Pot Reference
• ITC Reverses Brita's Water Filter Patent Win
• Drug Co. Again Seeks Toss Of $950M Vax Trade Secrets Case
• Too Many Patents Are Going To Large Cos., Economists Say
• Judge Slightly Pares Down Eye Software Trade Secrets Suit
• Patent Office Has Authority Over Petitions, Court Told
• Sandoz Can't Get New Trial After $39M Eyelash Serum IP Loss
• No COVID Coverage For Entertainment Co., Calif. Panel Says
• Mich. Panel Says Oncology Co. Owes Taxes On Lab Supplies
• Eastern District Of Mich. Judge To Take Inactive Status
• Estate Wants Full 10th Circ. To Review EMT Liability Claims
• Private Equity Owners Can Remedy Law Firms' Agency Issues
• ATS Corp. Buys Water Purification Equipment Co. For $195M
• Application Of Defend Trade Secrets Act Continues To Vary
• UK Litigation Roundup: Here's What You Missed In London
• Firm Fights Sanctions In Georgia-Pacific Unit's Bankruptcy
• Calif. Sues 'Predatory' Clinics Over 'Abortion Pill Reversal'
• Pomerantz To Be Lead Counsel In Mallinckrodt Investor Suit
• Gilead Sciences Gets Initial OK On $247M HIV Antitrust Deal
• Monsanto Funded Favorable Roundup Research, Jury Told
• Judge Tosses Suit Claiming Lead In Vitamin Shoppe Products
• Opioid MDL Special Master Fights Bias DQ For 'Email Mistake'
• La. Sued Again Over Changes To US Drug Discount Program
• Canadian Tribe Denied More Time To Appeal Purdue Injunction
• Yale, Prof. To Pay $1.5M And Share Drug Royalties In FCA Deal
• Drug Cabinet Finger Scans Are BIPA-Exempt, Ill. Justices Hear
• Pa. Nonprofit Says Ex-CFO's Whistleblower Suit Lacks NJ Ties
• Abbott Gets Partial Win In HIV Test Patent Feud With Novartis
• A Topic-Based Analysis Of FDA Responses To FOIA Requests
• Proving Causation Is Key To Fairness And Justice
• Fla. Nurse Convicted In $200M Medicare False Billing Scheme
• FTC Accuses PE Firm Of Raising Anesthesia Prices In Texas
• Skadden Nabs $19M Fee For 4 Months' Work On Endo Ch. 11
• Nelson Mullins Adds Dechert Trial Atty/Doctor In San Diego
• Fed. Circ. Affirms PTAB Ax Of Radiation Therapy Patent
• Arnold & Porter Adds Former Intel Corp. Atty in Washington
• Bradley Arant Fights Sanctions Bid Over Mid-Deposition Texts
• Feds Nab Plea Over Inside Info Stolen From BigLaw Associate
• Deals Rumor Mill: Disney, Mallinckrodt, XFL-USFL
• Tenn. AG Inks $44.5M Opioid Deal With Grocery Chain
• $10M Verdict Against Intuitive Lowered To Just A Dollar
• Supplement Co. Wants McCarter & English Win Slashed
• Sutter Health Owes $519M For Double-Billing, Trial Judge Told
• Stryker Appeals OsteoMed's Surgical Implant Patent Wins
• Mallinckrodt Gets Final OK For $250M Ch. 11 Financing
• Drug Cos. Don't Always Provide Required Discounts To Gov't
• House Bill Would Shield Psilocybin Legalization From DOJ
• Ill. Justices Mull Sending Suit Over Abbott Drug To Jury
• Biden Admin Extends Comment Period On Mental Health Regs
• Del. Justices Urged To Reverse AmerisourceBergen Dismissal
• NJ Judge Tosses Proposed Cannabis REIT Investor Suit
• Opiate MDL Special Master Faces DQ Bid Over 'Reply All' Goof
• Fed. Circ. Hands Win To Roche In Blood Drug Fight
• How To Protect Atty-Client Privilege While Using Generative AI
• Takeda Settles Gout Drug Antitrust Case Midtrial
• Orrick Adds MoFo Tech And Life Sciences IP Litigator In SF
• Arnold & Porter Opens Boston Office With Life Science Focus
• Humana Tries To Ax Walgreens' Claims Over Crowell & Moring
• Eli Lilly Launches 10 Suits Over New Diabetes Drug
• Merck Chided By AARP, Democrats Over Drug Price Suit
• New Jersey Shore Town Wants Pot Co.'s Zoning Suit Tossed
• Judge OKs Juul's $255M Deal, Bars AI Co.'s 'En Masse' Claims
• J&J Defends Texas Two-Step Talc Gambit To Lawmakers
• Texas Atty Blamed 'Brain Fart' For False Statement, SEC Says
• 1st Circ. Sides With J&J Subsidiary In Lactaid False Ad Suit
• Takeda Wants End To Gout Drug Antitrust Case Midtrial
• HIV Drug Case Against Gilead Threatens Medical Innovation
• Two Del. Suits Seek Info On $462M Paratek Deal's Losing Bids
• Valeant Says 9th Circ.'s FCA Disclosure Ruling Went Too Far
• How New Lawyers Can Leverage Feedback For Growth
• Doc Becomes 3rd Of 5 In Alexion Insider Case To Admit Guilt
• Regeneron Partly Agrees It Infringed COVID Tech Patent
• Maine Hospitals Urge High Court To Deny Review Of Vax Suit
• COVID Test Maker Lucira Gets OK For Ch. 11 Liquidation
• Boston Scientific To Buy MedTech Biz In $850M Cash Deal
• RICO Trade Secret Standard Prevails Within 9th Circ. Courts
• 2 Firms Help Swedish Drug Co. Sobi Raise $540M
• Walgreens Slams Crowell 'Hail Mary' To Avoid Ethics Hearing
• Inventor Tells Justices Amgen Ruling Dooms Alice
• Roundup's Cancer Link Has Solidified Over Time, Jury Hears
• FDA Warns Vape Cos. To Stop Selling 'Illegal' Products
• UK Antitrust Court Upholds £130M In Allergan Fines
• Mylan Hit With Patent Suit Over Generic Nausea Drug
• Target And P&G Sued Over 'Useless' Nasal Decongestant
• Catching Up With Delaware's Chancery Court
• MLB Stars Drop Al Jazeera Defamation Suits Over Doping Doc
• Sanofi Slams Mylan's 'Mishmash' Of Claims Over Insulin
• ESG Around The World: Australia
• Vedder Price Adds Ex-Nixon Peabody Litigator In Chicago
• Concerns For 510(k) Sponsors After FDA Proposes Major Shift
• High Court's New FCA Ruling Is Quickly Making Trials Likelier
• University Of Calif., MIT Top List Of Schools Getting Patents
• Teva Faces Massive Investor Suit Over Opioid Scandal Fallout
• Louisiana Lab Owner Gets 3 Years For Medicare Kickback Ploy
• Chamber Urges Court To Block Medicare Drug Price Program
• Justices Urged To Restore Suit Targeting PTAB's Fintiv Rule
• Biotech Firms Join IPO Wave After Raising $561M Combined
• GSK, P&G And Others Sued Over 'Ineffective Decongestants'
• Developers Are Testing Defenses In Generative AI Litigation
• Approval Regs Must Change To Keep Up With Biologics Tech
• Ex-Alexion Vice President Admits To Insider Trading Charges
• Address The Data Monopoly, Otherwise Tech Giants Control AI
• Minn. Product Case Highlights Challenges Of Misuse Defense
• UK Litigation Roundup: Here's What You Missed In London
• Novartis Shareholders OK Spinoff Of $9.6B Sandoz Unit
• Vaccine Maker Beats Investor Suit Over Private Investment
• Amyris Fails To Get Final OK On $190M DIP Loan
• P&G And J&J Sold Useless Decongestants, Suit Says
• 10x Beats Rival's Bid To Ax Genetics Patents As Ineligible
• Arm's Blockbuster IPO Likely To Clear Path For More Offerings
• Meta Must Face DC's COVID Vaccine Misinformation Subpoena
• Vyera Floats Rights Offering To Fix Ch. 11 Plan Objections
• Fed. Circ. Won't Touch Hypertension Drug Producer's Loss
• High Court's ID Theft Limits No Help To Drug Rep, Judge Says
• Pfizer, BioNTech Lob Counterclaims In MRNA Vax Tech Suit
• FTC Warns Drugmakers Against Listing Illegitimate Patents
• Abcam Founder Opposes Danaher Deal, Wants Board Gone
• Myovant, Sumitomo Deal Hurt By Skadden Conflict, Suit Says
• Biopharm Firm Hit With 2nd Suit Alleging Unpaid Wages
• Ex-Pfizer Worker To Stand Trial In Paxlovid Insider Case
• The Impact Of A Del. District's Procedural Shift On Disclosures
• Twitter Legal Fees Suit Offers Crash Course In Billing Ethics
• Product Liability Claims Rose Over 5 Years, Report Says
• Roundup Agricultural Use Irrelevant To Cancer Suit, Jury Told
• Alexion Inks $125M Deal In Investors' Suit Over Sales Tactics
• Medicaid Agency's Immunity From Retaliation Claim Affirmed
• Old Offer To Drop Chancery Case Roils Bioverativ Settlement
• Cardinal Health, Investors Get Final OK For $109M Settlement
• AbbVie Asks Court To Compel IRS Docs For $1.6B Dispute
• Medical Device Cos. Fight To Toss Conn. Birth Control Suits
• Leveraging The Strategic Pause In Patent Prosecution
• EU Privacy Framework Bodes Well For US Life Sciences Cos.
• Shkreli-Tied Pharma Co. Cleared For $650K Ch. 11 Sale
• Laws Based On Rapid Drug Tests Are Unscientific And Unfair
• Amgen-Horizon Deal May Signal FTC's Return To Bargaining
• Integra Downplayed FDA Factory Warnings, Investor Suit Says
• Calif. Lawmakers Pass Pioneering Carbon Disclosure Bill
• Sorrento OK'd For Alternative $110M Ch. 11 Stock Sale
• Insurers Seek Toss Of Foam Co.'s Chemical Coverage Suit
• HHS Assails Merck's 'Misunderstandings' Of Drug Pricing Law
• Organizations Urge Texas Courts To Curb 'Judge Shopping'
• Women Denied Abortions Launch Complaints In 3 States
• Fed. Circ. Backs Apple's PTAB Wins In Masimo Patent War
• 5th Circ. Presses Illumina On Cancer Test Competition
• Opioid Sales Fell By Half After 2010, DEA Data Shows
• Prisoner, 3 Others Cop To $25M COVID Relief Fraud
• SEC Hits Health Care Co. And Owner With $2.7M Fraud Suit
• BigLaw Associate's Ex Faces January Insider Trading Trial
• Indian Co. Urges Fed. Circ. To Back Obviousness Of Oxy IP
• Amgen Patent Ruling's Impact Extends Beyond Life Sciences
• 6th Circ. Asks Ohio Justices To Settle $650M Opioid Question
• Minn. Catering Biz Owners Cop To $250M Child Meals Scheme
• Latham, Quinn Emanuel Pressed For Docs In Antitrust Case
• InterMune Ex-CEO's Atty Pressed To Defend Legal Fees In Del.
• Pharma Cos. Say Twitter Terror Ruling Requires DC Circ. Redo
• 9th Circ. Judges Open To Reviving Ariz. Abortion Law Fight
• HCA Healthcare Sued In Fla. Over Data Breach Of 11M Patients
• Nitrous Distributor Hit With $700M Verdict Over Crash Death
• Justices Told Ax Of Vitamin Patent Creates Fed. Circ. Split
• Catching Up With Delaware's Chancery Court
• Attys Tout Need For Diverse IP Trial Counsel Amid Skepticism
• ABA's Money-Laundering Resolution Is A Balancing Act
• 8 Ways Life Sciences Cos. Can Adapt To The Social Media Era
• Pool Supply Co. Investors Say COVID Panic Inflated Sales
• 2 Biotech Firms Hope To Tap Thawing IPO Market For $495M
• Doctor Wants J&J Unit's Libel Suit Over Talc Study Tossed
• What Is The Proper Breadth Of An IPR Reply?
• NJ Lab Says Alliant Owes Payment For COVID-19 Testing
• Feds Fight Texas Atty's Bid To Toss Kickback Conviction
• J&J Talc Unit Questions Distress Need In Ch. 11 Appeal
• Fla. Justices Question Abortion's Inclusion In Privacy Right
• Biotech Firm Accused Of 'Gaslighting' In $41M Share Award Suit
• Fed. Circ. Asks What's New About Schizophrenia Drug Patent
• Ex-AstraZeneca Sales Rep Seeks Cert. In Age Bias Action
• HHS Proposes 'Historic' Rule Combating Disability Bias
• PTAB Axes RapidPulse Blood Clot Removal Patent
• Defendant In Harvard Body Theft Case Pleads Guilty
• Recalled Lentil Crumbles Cost Woman Gallbladder, Suit Says
• Fresenius Gets 13 Cases Trimmed From Dialysis MDL
• Justices Urged To Hear Fight Over Abortion Pill Restrictions
• With Equity Markets Down, Venture Lending Provides Solution
• Former Biotech Execs Avoid Prison In Stock Tip Case
• UK Litigation Roundup: Here's What You Missed In London
• Kroger To Pay Up To $1.4B To End Opioid Claims
• Kraft Heinz Must Face Crystal Light False Ad Suit
• Biotech Fired Remote Exec Who Declined Vax, Suit Says
• Rival Gene Sequencing Cos. Must Face November Patent Trial
• Psychedelics Decriminalization Bill Clears Calif. Legislature
• Astellas Drops Suit Over Medicare Drug Price Negotiation Law
• Walgreens Cuts $44M Deal To End Theranos Consumer Suits
• Amyris To Pay Up To $750K In Creditor Group Atty Fees
• Texans Say Claims Court Can't Take Biometrics Fee Suit
• UK Competition Regulator Reviewing Veterinary Industry
• Law Firm Professional Development Steps To Thrive In AI Era
• Consumer Group Backs Ga. Doctor's Appeal In Roundup Suit
• HHS Neuromonitoring Advisory May Have Broad Relevance
• Enhanced Patent Damages: Trends IP Attorneys Should Know
• Attys Vie To Lead Investor Suit Against AI-Based Drugmaker
• Philips Inks $479M Economic Losses Deal In CPAP Recall MDL
• Actelion Ducks RICO Suit Over Hypertension Drugs, For Now
• Altria's $45M Deal With Vapers Over Unsafe E-Cigs Wins OK
• Indoor Farming Co. AppHarvest OK'd For Ch. 11 Asset Sales
• Pomerantz Seeks To Lead Mallinckrodt Investor Suit
• Mass. AG Certifies 2 Psychedelics Legalization Efforts
• FTC-Amgen Deal: 'Major Advance,' Or 'Narrow Assurance'?
• Ga. Judge Pauses Block Of Ban On Trans Youths' Health Care
• Wholesalers Tell Pa. Jury Takeda Delayed Generic Gout Drug
• Ex-Amgen Exec's Startup Settles With Amgen
• 3 Firms Build Up To $600M Sale Of Medical Device Biz
• Uncertain Copyright And Patent Protections In The AI Age
• SmileDirectClub Can't Ax Rival's Bid To Beat Patent Claims
• TM Suit Doesn't Belong In Michigan, Judge Says
• Chancery Upholds AbbVie Damages In Takeda-Lupron Suit
• Veolia Tries To Halt Discovery Into PR Plan In Flint Water Case
• Natera Cancer Test Patents Upheld In Wake Of $19M Verdict
• LA County Says Pharmacy Benefit Cos. Fueled Opioid Crisis
• 'I'm Baffled,' Fed. Circ. Judge Tells Purdue Amid PTAB Appeal
• Emergent Gets Investor Suit Over COVID Vaccine Trimmed
• Chancery Finds Drug Exec Breached Pact With Sorrento
• How Section 101 Claims Can Trigger Invalidity Under Alice
• Potential Marijuana Status Change Would Shift Industry Risks
• Scientist Says Biopharma Firm Withholding Wages
• Investors Say Cannabis Co. Board Hid SEC Investigation
• Unilever Sued Over Injury From Recalled Laundress Product
• Novartis Joins Legal Fray After Price Negotiation List Unveiled
• Hearing Aid Investors Lose 2nd Bid At Suit Over DOJ Probe
• Ga. Asks Court To Rethink Block On State's Trans Health Ban
• NJ Court OKs Cannabis Permits To 'Women-Owned' Cos.
• NC Justices Give Software Maker 2nd Shot At Contract Claims
• Gilead-Backed Stem Cell Startup Beats Patent Suit
• Off The Bench: Sports & Betting Law News You Need To Know
• Biden Pot Reform Effort Puts DEA In Hot Seat
• Trending At The PTAB: Cautionary Tale Of VLSI Challenger
• Atty Tells 9th Circ. Valeant Ruling Saves Allergan Patent Suit
• Mich. Parents Seek $423K Atty Fees, Costs For Infant Data Win
• UK Litigation Roundup: Here's What You Missed In London
• Attys Prepare For IPO Pickup As Market Shows Signs Of Life
• Amgen Gets FTC Green Light On $28B Horizon Deal